PA3-109

antibody from Invitrogen Antibodies

Targeting: SSTR2

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA3-109

Provider

Invitrogen Antibodies

Product name

SSTR2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

PA3-109 detects Somatostatin Receptor 2A in human and rat samples.

Concentration

Conc. Not Determined

References

Submitted references

Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue.

Peculis R, Mandrika I, Petrovska R, Dortane R, Megnis K, Nazarovs J, Balcere I, Stukens J, Konrade I, Pirags V, Klovins J, Rovite V
Frontiers in endocrinology 2020;11:313

---

Loss of IQSEC3 Disrupts GABAergic Synapse Maintenance and Decreases Somatostatin Expression in the Hippocampus.

Kim S, Kim H, Park D, Kim J, Hong J, Kim JS, Jung H, Kim D, Cheong E, Ko J, Um JW
Cell reports 2020 Feb 11;30(6):1995-2005.e5

---

Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.

Sizdahkhani S, Feldman MJ, Piazza MG, Ksendzovsky A, Edwards NA, Ray-Chaudhury A, Maric D, Merrill MJ, Pacak K, Zhuang Z, Chittiboina P
Scientific reports 2017 Jan 17;7:40822

---

SSTR2-based reporters for assessing gene transfer into non-small cell lung cancer: evaluation using an intrathoracic mouse model.

Singh SP, Han L, Murali R, Solis L, Roth J, Ji L, Wistuba I, Kundra V
Human gene therapy 2011 Jan;22(1):55-64

---

Noninvasive repetitive imaging of somatostatin receptor 2 gene transfer with positron emission tomography.

Cotugno G, Aurilio M, Annunziata P, Capalbo A, Faella A, Rinaldi V, Strisciuglio C, Di Tommaso M, Aloj L, Auricchio A
Human gene therapy 2011 Feb;22(2):189-96

---

Tumor-induced hypophosphatemic rickets in an adolescent boy--clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue.

Haeusler G, Freilinger M, Dominkus M, Egerbacher M, Amann G, Kolb A, Schlegel W, Raimann A, Staudenherz A
The Journal of clinical endocrinology and metabolism 2010 Oct;95(10):4511-7

---

Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy.

Mundschenk J, Unger N, Schulz S, Höllt V, Schulz S, Steinke R, Lehnert H
The Journal of clinical endocrinology and metabolism 2003 Nov;88(11):5150-7

---

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies.

Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, Arnold R
Gut 2002 Jan;50(1):52-60

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis was performed on whole cell extracts (30 µg lysate) of SH-SY5Y (Lane1), U-87 MG (Lane 2), HeLa (Lane 3) and CaCo-2 (lane 4). The blots were probed with Anti-Somatostatin Receptor 2A Rabbit Polyclonal Antibody (Product # PA3-109, 1:250 dilution) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.4 µg/mL, 1:2500 dilution). A 60 kDa band corresponding to Somatostatin Receptor 2A was observed across cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel (Product # NP0302BOX), XCell SureLock™ Electrophoresis System (Product # EI0002), and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of SSTR2A in human pancreatic islands using Product # PA3-109.

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry analysis of Somatostatin Receptor 2A was done on SH-SY5Y cells. Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with Somatostatin Receptor 2A Rabbit Polyclonal Antibody (PA3109, red histogram) or with rabbit isotype control (pink histogram) at 3-5 ug/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Goat Anti-Rabbit Secondary Antibody (A11008) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10,000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 Von Hippel Lindau Disease related hemangioblastomas express somatostatin receptors. Patients with von Hippel Lindau disease (VHL) undergoing surgical resection of posterior fossa hemangioblastoma provide confirmation of DOTATATE avidity of these lesions. The post-operative T1 weighted MRI image ( A ) and DOTATATE PET image ( B ) confirm complete resection of a DOTATATE avid posterior fossa hemangioblastoma ( C , D ). Representative images ( E ) of anti-SSTR IHC staining classified as negative (i), positive/negative (ii), positive (iii), double positive (iv) or triple positive (v). Scale bar = 50 mum. Average staining intensity for each SSTR subtype is shown in panel F. Number of tumors with SSTR expression are categorized by receptor subtype ( G ). Positive staining patterns were found in 8/9 tumors against SSTR1, in 8/9 tumors against SSTR2a, in 2/9 tumors against SSTR3, in 9/9 tumors against SSTR4, and in 8/9 tumors in SSTR5.